Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Lupin, Sun Pharma gain nearly 2% as USFDA approves Armodafinil, Paroxetine

US FDA also approved ANDA for Paroxetine Hydrochloride that filed by Sun Pharma.

July 19, 2017 / 02:51 PM IST
Myth 3: Everyone who has a mental illness needs medication to manage symptoms | Bulthuis says no two patients are the same. While medicines can help manage symptoms, there are some people with mental illness who do not require medication. For others, medicine is essential for recovery. (Representative image)

Myth 3: Everyone who has a mental illness needs medication to manage symptoms | Bulthuis says no two patients are the same. While medicines can help manage symptoms, there are some people with mental illness who do not require medication. For others, medicine is essential for recovery. (Representative image)

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Lupin and Sun Pharma shares gained 1.8 percent each intraday Wednesday after receiving approval from the US health regulator for drugs.

Pharma major Lupin has received approval from US Food and Drug Administration for Armodafinil that is used to treat excessive sleeping disorder.

US FDA also approved ANDA for Paroxetine Hydrochloride that filed by Sun Pharma.

Paroxetine Hydrochloride is used for treatment of OCD, panic attacks.

Meanwhile, Aurobindo Pharma also received US FDA approval for Sevelamer tablets that are used to treat patients with chronic kidney diseases and Zydus Pharma, the subsidiary of Cadila Healthcare, got approval for Pitavastatin that helps lowering bad cholesterol & raising good cholesterol.

At 14:25 hours IST, the stock price of Lupin was quoting at Rs 1,171.05, up 1.33 percent and Sun Pharmaceutical Industries was at Rs 585.95, up 1.37 percent on the BSE.

Posted by Sunil Shankar Matkar

first published: Jul 19, 2017 02:51 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347